Treatment of rectal chlamydia infection may be more complicated than we originally thought

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 4, 2014, Pages 961-964

  Hocking, Jane S ^a   Kong, Fabian Y S ^a   Timms, Peter ^b   Huston, Wilhelmina M ^c   Tabrizi, Sepehr N ^d,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF THE SUNSHINE COAST   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Azithromycin; Doxycycline; Treatment failure

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; DOXYCYCLINE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; CHLAMYDIASIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TISSUE LEVEL; DRUG TRANSPORT; DRUG TREATMENT FAILURE; GASTROINTESTINAL TRACT; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOGRANULOMA VENEREUM; MICROFLORA; MINIMUM INHIBITORY CONCENTRATION; NUCLEIC ACID ANALYSIS; PHARMACOKINETICS; RECTAL CHLAMYDIA INFECTION; RECTAL MICROBIOME; RECTAL TISSUE; RECTUM; SCREENING TEST; STOMACH MUCOSA; CHLAMYDIA INFECTIONS; FEMALE; MALE; MALE HOMOSEXUALITY; RECTAL DISEASES; SEXUAL BEHAVIOR; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHLAMYDIA INFECTIONS; DOXYCYCLINE; FEMALE; HOMOSEXUALITY, MALE; HUMANS; MALE; RECTAL DISEASES; SEXUAL BEHAVIOR; TREATMENT FAILURE;

EID: 84926473214     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku493     Document Type: Article

References (35)

1. WHO. Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections-2008. Geneva: WHO, 2012. http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/.
2. National Notifiable Diseases Surveillance System. Number of Notifications of Chlamydial Infections, Australia, by Age Group and Sex. 2013. http://www9.health.gov.au/cda/source/rpt_4_sel.cfm.
3. PHE. Table 1: STI Diagnoses and Rates in England by Gender, 2004 to 2013. https://www.gov.uk/government/statistics/sexually-transmittedinfections- stis-annual-data-tables.
4. Lewis D, Newton D, Guy R et al. The prevalence of Chlamydia trachomatis infection in Australia: a systematic review and meta-analysis. BMC Infect Dis 2012; 12: 113.
5. Mercer CH, Tanton C, Prah P et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 2013; 382: 1781-94.
6. van Liere G, Hoebe C, Wolffs P et al. High co-occurrence of anorectal chlamydia with urogenital chlamydia in women visiting an STI clinic revealed by routine universal testing in an observational study; a recommendation towards a better anorectal chlamydia control in women. BMC Infect Dis 2014; 14: 274.
7. Rank RG, Yeruva L. 'Hidden in plain sight:' chlamydial gastrointestinal infection and its relevance to 'persistence' in human genital infections. Infect Immun 2014; 82: 1362-71.
8. Fleming DT, Wasserheit JN. Fromepidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75: 3-17.
9. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010; 59: 44-9. http://www.cdc.gov/std/treatment/2010/std-treatment-2010-rr5912.pdf.
10. Khosropour CM, Dombrowski JC, Barbee LA et al. Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection:a retrospective cohort study. Sex Transm Dis 2014; 41: 79-85.
11. Kong FYS, Vodstrcil L, Tabrizi SN et al. The efficacy of azithromycin for the treatment of rectal chlamydia infection-a systematic review and meta-analysis. In: Abstracts of the Thirteenth International Symposium on Human Chlamydial Infections, Pacific Grove, CA, 2014. Abstract, Section 5 Sexually Transmitted Infections, p. 353. International Chlamydia Symposium, San Francisco, CA, USA.
12. Worm AM, Osterlind A. Azithromycin levels in cervical mucus and plasma after a single 1.0 g oral dose for chlamydial cervicitis. Genitourin Med 1995; 71: 244-6.
13. Krohn K. Gynecological tissue levels of azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10: 864-8.
14. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 Suppl A: 73-82.
15. Lalak N, Morris D. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 370-4.
16. Heiligenberg M, Lutter R, Pajkrt D et al. Effect of HIV and chlamydia infection on rectal inflammation and cytokine concentrations in men who have sex with men. Clin Vacc Immunol 2013; 20: 1517-23.
17. Parnham MJ, Haber VE, Giamarellos-Bourboulis EJ et al. Azithromycin:mechanisms of action and their relevance for clinical applications. Pharmacol Ther 2014; 143: 225-45.
18. Cunha BA, Sibley CM, Ristuccia AM. Doxycycline. Ther Drug Monit 1982; 4: 115-35.
19. Höjer H, Wetterfors J. Concentration of doxycycline in bowel tissue and postoperative infections. Scand J Infect Dis Suppl 1975; 100-5.
20. Hogan RJ, Mathews SA, Mukhopadhyay S et al. Chlamydial persistence:beyond the biphasic paradigm. Infect Immun 2004; 72: 1843-55.
21. Kintner J, Lajoie D, Hall J et al. Commonly prescribed b-lactam antibiotics induce C. trachomatis persistence/stress in culture at physiologically relevant concentrations. Front Cell Infect Microbiol 2014; 4: 44.
22. Phillips-Campbell R, Kintner J, Schoborg RV. Induction of the Chlamydia muridarum stress/persistence response increases azithromycin treatment failure in a murine model of infection. Antimicrob Agents Chemother 2014; 58: 1782-4.
23. Reveneau N, Crane DD, Fischer E et al. Bactericidal activity of firstchoice antibiotics against gamma interferon-induced persistent infection of human epithelial cells by Chlamydia trachomatis. Antimicrob Agents Chemother 2005; 49: 1787-93.
24. Bragina EY, Gomberg MA, Dmitriev GA. Electron microscopic evidence of persistent chlamydial infection following treatment. J Eur Acad Dermatol Venereol 2001; 15: 405-9.
25. Van Boeckel TP, Gandra S, Ashok A et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014; 14: 742-50.
26. Patton M, Su J, Nelson R et al. Primary and secondary syphilis-United States, 2005-2013. MMWR 2014; 63: 402-6.
27. Belland RJ, Nelson DE, Virok D et al. Transcriptome analysis of chlamydial growth during IFN-g-mediated persistence and reactivation. Proc Natl Acad Sci USA 2003; 100: 15971-6.
28. Lewis ME, Belland RJ, Abdelrahman YM et al. Morphologic and molecular evaluation of Chlamydia trachomatis growth in human endocervix reveals distinct growth patterns. Front Cell Infect Microbiol 2014; 4: 71.
29. Horner PJ. Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy. Sex Transm Infect 2012; 88: 154-6.
30. Dukers-Muijrers NHTM, Speksnijder AGCL, MorréSA et al. Detection of anorectal and cervicovaginal Chlamydia trachomatis infections following azithromycin treatment: prospective cohort study with multiple timesequential measures of rRNA, DNA, quantitative load and symptoms. PLoS One 2013; 8: e81236.
31. de Vrieze NHN, van Rooijen M, Schim van der Loeff MF et al. Anorectal and inguinal lymphogranuloma venereum among men who have sex with men in Amsterdam, the Netherlands: trends over time, symptomatology and concurrent infections. Sex Transm Infect 2013; 89: 548-52.
32. Haar K, Dudareva-Vizule S, Wisplinghoff H et al. Lymphogranuloma venereum in men screened for pharyngeal and rectal infection, Germany. Emerg Infect Dis 2013; 19: 488-92.
33. Annan N, Sullivan A, Nori A et al. Rectal chlamydia-a reservoir of undiagnosed infection in men who have sex with men. Sex Transm Inf 2009; 85: 176-9.
34. Peuchant O, Duvert JP, Clerc M et al. Effects of antibiotics on Chlamydia trachomatis viability as determined by real-time quantitative PCR. J Med Microbiol 2011; 60: 508-14.
35. Amsden GW, Nafziger AN, Foulds G. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrob Agents Chemother 1999; 43: 163-5.